Effect of Protective Measures on the Risk of SARS-CoV-2 Infection among Eye Clinic Staff Members

Abstract

Background Switzerland was strongly affected by the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that resulted in a nationwide lockdown in March 2020. Ophthalmologists were at most risk of contracting a SARS-CoV-2 infection due to their close working distance from patients. The aim of the study is to evaluate the overall effectiveness of protective measures on the risk of SARS-CoV-2 infection among employees in a large public eye hospital.

Material and Methods After lifting the lockdown in April 2020, standard precaution measures were taken, such as no handshaking and the use of operating face masks and a protective plastic shield on slit lamps and diagnostic devices. Only patients with no signs of SARS-CoV-2 disease were seen during the study period. Specific anti-SARS-CoV-2 IgG antibody titers were measured in eye clinic employees at the end of April 2020 (1st test phase) and in January 2021 (2nd test phase). The prevalence of SARS-CoV-2 IgG antibody titers among employees with daily patient contact was compared to staff members with no patient contact.

Results The SARS-CoV-2 prevalence in employees with daily patient contact, with 0% in the 1st phase and 7.4% in the 2nd phase, was not significantly higher than the prevalence in the control group with no patient contact (0.9% in the 1st phase, p = 0.4; and 8.6% in the 2nd phase, p = 0.8). Furthermore, physicians were not at a significantly higher risk of SARS-CoV-2 infection compared to technicians, nurses, or office staff.

Conclusions This study shows that the abovementioned precaution measurements are effective in preventing transmission of SARS-CoV-2 infection in eye hospitals and enable us to resume practicing ophthalmology in a safe manner.

Zusammenfassung

Hintergrund Die Schweiz wurde in der 1. Welle der SARS-CoV-2-Pandemie stark getroffen und hatte im März 2020 einen nationalen Lockdown eingeführt. Ein besonders hohes Ansteckungsrisiko wurde bei Ophthalmolog*innen und Mitarbeitenden der Augenkliniken vermerkt, aufgrund des geringen räumlichen Abstands bei der Untersuchung der Patienten. Das Ziel der Studie ist es, die Wirksamkeit von Schutzmaßnahmen auf das Übertragungsrisiko einer SARS-CoV-2-Infektion auf die Mitarbeitenden einer großen Augenklinik zu beurteilen.

Material und Methoden Nach dem Aufheben des Lockdowns im April 2020 wurden viele Schutzmaßnahmen, wie z. B. das Tragen von Mund-Nase-Schutzmasken für alle Patienten und Mitarbeitenden, die Installation der Plastikschutzfolien an der Spaltlampe und diagnostischen Geräten, eingeführt sowie ein Verzicht auf Händeschütteln etabliert. Während der Studienzeit wurden ausschließlich asymptomatische, afebrile Patienten in der Augenklinik untersucht. Es erfolgte im April 2020 (1. Testphase) und im Januar 2021 (2. Testphase) eine Messung spezifischer Anti-SARS-CoV-2-IgG-Antikörper bei allen Mitarbeitenden der Augenkliniken. Es wurde die Prävalenz der SARS-CoV-2-IgG-Antikörper zwischen den Mitarbeitenden mit und ohne Patientenkontakt verglichen.

Resultate Die Prävalenz der SARS-CoV-2-IgG-Antikörper in Mitarbeitenden mit Patientenkontakt war im Vergleich zu Mitarbeitenden ohne Patientenkontakt sowohl in der 1. Testphase (0,0 vs. 0,9%; p = 0,4) als auch in der 2. Testphase (7,4 vs. 8,6%; p = 0,8) nicht signifikant unterschiedlich. Auch das ärztliche Personal war nicht häufiger betroffen als das restliche medizinische und nicht medizinische Personal. Die Prävalenz bei Mitarbeitenden mit einer privaten Exposition zu SARS-CoV-2 war signifikant höher als bei beruflicher Exposition.

Schlussfolgerung Unter Einhaltung der oben genannten Schutzmaßnahmen konnte gezeigt werden, dass ein vergleichbares Übertragungsrisiko einer SARS-CoV-2-Infektion bei Mitarbeitenden der Augenklinik mit und ohne direkten Patientenkontakt besteht. Ein höheres Ansteckungsrisiko wurde lediglich nach Exposition zu einer SARS-CoV-2-positiven Person im privaten Umfeld detektiert.

Key words

conjunctiva - infectious diseases - microbiology

Schlüsselwörter

Mikrobiologie - Infektiologie - Bindehaut

Publication History

Received: 26 September 2021

Accepted: 27 February 2022

Article published online:
26 April 2022

• References

• 1 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506 DOI: 10.1016/S0140-6736(20)30183-5.
• 2 Jørstad ØK, Moe MC, Eriksen K. et al. Coronavirus disease 2019 (COVID-19) outbreak at the Department of Ophthalmology, Oslo University Hospital, Norway. Acta Ophthalmol 2020; 98: e388-e389 DOI: 10.1111/aos.14426.
• 3 Romano MR, Montericcio A, Montalbano C. et al. Facing COVID-19 in Ophthalmology Department. Curr Eye Res 2020; 45: 653-658 DOI: 10.1080/02713683.2020.1752737.
• 4 Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet 2020; 395: e39 DOI: 10.1016/s0140-6736(20)30313-5.
• 5 Toro MD, Brezin AP, Burdon M. et al. Early impact of COVID-19 outbreak on eye care: Insights from EUROCOVCAT group. Eur J Ophthalmol 2021; 31: 5-9 DOI: 10.1177/1120672120960339.
• 6 Arruabarrena C, Toro MD, Onen M. et al. Impact on Visual Acuity in Neovascular Age Related Macular Degeneration (nAMD) in Europe Due to COVID-19 Pandemic Lockdown. J Clin Med 2021; 10: 3281 DOI: 10.3390/jcm10153281.
• 7 Toro M, Choragiewicz T, Posarelli C. et al. Early Impact of COVID-19 Outbreak on the Availability of Cornea Donors: Warnings and Recommendations. Clin Ophthalmol 2020; 14: 2879-2882 DOI: 10.2147/OPTH.S260960.
• 8 Elfalah M, AlRyalat SA, Toro MD. et al. Delayed Intravitreal Anti-VEGF Therapy for Patients During the COVID-19 Lockdown: An Ethical Endeavor. Clin Ophthalmol 2021; 15: 661-669 DOI: 10.2147/OPTH.S289068.
• 9 Toro MD, Bremond-Gignac D, Brezin AP. et al. COVID-19 outbreak and increased risk of amblyopia and epidemic myopia: Insights from EUROCOVCAT group. Eur J Ophthalmol 2022; 32: 17-22 DOI: 10.1177/11206721211053175.
• 10 Scorcia V, Giannaccare G, Gatti V. et al. Intravitreal Dexamethasone Implant in Patients Who Did Not Complete Anti-VEGF Loading Dose During the COVID-19 Pandemic: a Retrospective Observational Study. Ophthalmol Ther 2021; 10: 1015-1024 DOI: 10.1007/s40123-021-00395-6.
• 11 Bajka A, Wiest MRJ, Hamann T. et al. Assessment of Patientsʼ Confidence Regarding a New Triage Concept in a Medical Retina Clinic during the First COVID-19 Outbreak. Int J Environ Res Public Health 2021; 18: 5846 DOI: 10.3390/ijerph18115846.
• 12 Olivia Li JP, Shantha J, Wong TY. et al. Preparedness among Ophthalmologists: During and Beyond the COVID-19 Pandemic. Ophthalmology 2020; 127: 569-572 DOI: 10.1016/j.ophtha.2020.03.037.
• 13 Nguyen LH, Drew DA, Graham MS. et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health 2020; 5: e475-e483 DOI: 10.1016/s2468-2667(20)30164-x.
• 14 Zhou L, Xu Z, Castiglione GM. et al. ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection. Ocul Surf 2020; 18: 537-544 DOI: 10.1016/j.jtos.2020.06.007.
• 15 Klingenstein M, Klingenstein S, Neckel PH. et al. Evidence of SARS-CoV2 Entry Protein ACE2 in the Human Nose and Olfactory Bulb. Cells Tissues Organs 2020; 209: 155-164 DOI: 10.1159/000513040.
• 16 Dolar-Szczasny J, Toro MD, Dworzanska A. et al. Ocular Involvement of SARS-CoV-2 in a Polish Cohort of COVID-19-Positive Patients. Int J Environ Res Public Health 2021; 18: 2916 DOI: 10.3390/ijerph18062916.
• 17 dellʼOmo R, Filippelli M, Semeraro F. et al. Effects of the first month of lockdown for COVID-19 in Italy: A preliminary analysis on the eyecare system from six centers. Eur J Ophthalmol 2021; 31: 2252-2258 DOI: 10.1177/1120672120953074.
• 18 Aggarwal S, Jain P, Jain A. COVID-19 and cataract surgery backlog in Medicare beneficiaries. J Cataract Refract Surg 2020; 46: 1530-1533 DOI: 10.1097/j.jcrs.0000000000000337.
• 19 Cummings AB, Gildea C, Brezin AP. et al. Impact on refractive surgery due to increasing use of personal protection equipment: Insights from EUROCOVCAT group. Eur J Ophthalmol 2021; 31: 2789-2793 DOI: 10.1177/11206721211018641.
• 20 Tognetto D, Brezin AP, Cummings AB. et al. Rethinking Elective Cataract Surgery Diagnostics, Assessments, and Tools after the COVID-19 Pandemic Experience and Beyond: Insights from the EUROCOVCAT Group. Diagnostics (Basel) 2020; 10: 1035 DOI: 10.3390/diagnostics10121035.
• 21 Veritti D, Sarao V, Bandello F. et al. Infection control measures in ophthalmology during the COVID-19 outbreak: A narrative review from an early experience in Italy. Eur J Ophthalmol 2020; 30: 621-628 DOI: 10.1177/1120672120927865.
• 22 Kuo IC. Clinical Experience of an American Academic Ophthalmology Department During the COVID-19 Pandemic. Qual Manag Health Care 2022; DOI: 10.1097/QMH.0000000000000358.
• 23 Société Française dʼOphtalmologie. [Recommendations on personal protective measures in ophthalmology (French Ophthalmology Society and National Council of Professionals in Ophthalmology) during this COVID-19 pandemic]. J Fr Ophtalmol 2020; 43: 529-530 DOI: 10.1016/j.jfo.2020.04.009.
• 24 Jacob JT, Baker JM, Fridkin SK. et al. Risk Factors Associated With SARS-CoV-2 Seropositivity Among US Health Care Personnel. JAMA Netw Open 2021; 4: e211283 DOI: 10.1001/jamanetworkopen.2021.1283.
• 25 Steensels D, Oris E, Coninx L. et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. JAMA 2020; 324: 195-197 DOI: 10.1001/jama.2020.11160.
• 26 Hunter BR, Dbeibo L, Weaver CS. et al. Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare workers with differing levels of coronavirus disease 2019 (COVID-19) patient exposure. Infect Control Hosp Epidemiol 2020; 41: 1441-1442 DOI: 10.1017/ice.2020.390.
• 27 Iversen K, Bundgaard H, Hasselbalch RB. et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. Lancet Infect Dis 2020; 20: 1401-1408 DOI: 10.1016/S1473-3099(20)30589-2.
• 28 Jespersen S, Mikkelsen S, Greve T. et al. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Survey Among 17 971 Healthcare and Administrative Personnel at Hospitals, Prehospital Services, and Specialist Practitioners in the Central Denmark Region. Clin Infect Dis 2021; 73: e2853-e2860 DOI: 10.1093/cid/ciaa1471.
• 29 Mansour M, Leven E, Muellers K. et al. Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City. J Gen Intern Med 2020; 35: 2485-2486 DOI: 10.1007/s11606-020-05926-8.
• 30 Ferrara M, Romano V, Steel DH. et al. Reshaping ophthalmology training after COVID-19 pandemic. Eye (Lond) 2020; 34: 2089-2097 DOI: 10.1038/s41433-020-1061-3.